Yes, China-originated drug candidates are part of a growing licensing and sourcing trend—but the available reporting does not identify a list of big-pharma buyers or specific assets they are currently evaluating. The October 6, 2026, CNBC interview listing uses the headline “Large biopharma companies looking at China assets right now,” but does not name companies or deals. Goldman Sachs Research describes the broader forces behind buyer interest: large drugmakers need new pipeline candidates as patents expire, and China has become a significant source of biotech innovation.
What the headline establishes—and what it doesn’t
The headline reflects an analyst’s view of a market trend, not confirmation of undisclosed negotiations. Goldman Sachs Research’s July 10, 2026, analysis says large-cap biopharma companies are seeking innovation to replenish pipelines and address losses of exclusivity. It also describes China as an important source of innovation and a sought-after place to run clinical trials.
Those points support the claim that large companies are looking beyond their existing portfolios and that China is among the places they are looking. They do not establish which buyer is assessing which drug candidate, whether an assessment has advanced to talks, or whether any deal will close. A licensing agreement gives rights to develop or commercialize an asset under agreed terms; it is not necessarily an acquisition of the company that originated it.
Why large drugmakers are seeking outside assets
Pipeline gaps and patent expirations
Goldman Sachs Research attributes deal appetite to two linked pressures: companies need new medicines to replenish their development pipelines, and they must prepare for revenue exposure as existing products lose exclusivity. Salveen Richter, a Goldman Sachs analyst, put the pipeline need this way: “Large biopharma firms are constantly searching for innovation to fill their pipelines.” Goldman’s July 2026 analysis also identifies oncology, immunology, neuroscience, and cardiometabolic health as potential areas for mergers and acquisitions.
#1 Best Overall
BeInCrypto reported on October 7, 2026, that Richter estimated about $440 billion in drugs would lose patent protection through 2032. That figure is attributed to Richter through BeInCrypto; it is not independently confirmed here as a Goldman Sachs estimate. It describes a broad industry exposure, not a forecast that all affected sales will disappear or be replaced through deals.
China’s growing role in external innovation
Boston Consulting Group’s 2026 report estimates that China accounts for about 30% of the global biotech pipeline and that Chinese firms account for about 50% of new antibody-drug conjugates. BCG also says transactions involving China represented almost half of licensing activity in 2025. These measures describe the scale and mix of pipeline and deal activity; they do not show that every candidate is clinically successful, commercially attractive, or suitable for a particular buyer.
What the market figures say
| Measure | Reported figure | How to interpret it |
|---|---|---|
| Licensing activity involving China | Almost half in 2025 | BCG’s 2026 report; a share of licensing activity, not a count of completed acquisitions or proof of deal success. |
| China’s share of the global biotech pipeline | About 30% | BCG’s estimate in its 2026 report; it describes pipeline contribution, not the probability that candidates will reach market. |
| New antibody-drug conjugates from Chinese firms | About 50% | BCG’s estimate in its 2026 report; it concerns this modality, not all drug development. |
| Change in Chinese asset valuations | Rose 150% over the prior year | BCG’s 2026 report estimate. It is not a guarantee of value, buyer demand, or eventual transaction terms. |
The figures make China difficult for global dealmakers to ignore, but they answer different questions: how much licensing activity involves China, how much pipeline originates there, and how concentrated a particular drug modality has become. None alone tells an investor whether a specific deal is attractive.
What buyers need to diligence before licensing an asset
A large licensing market does not resolve the central question for any individual candidate: whether its evidence, commercial potential, and deal terms justify the cost and risk. Key checks include:
- Clinical evidence and stage: Assess the maturity of human data, trial design, comparator, and whether results are likely to translate across patient populations and regions.
- Differentiation: Examine the mechanism, observed efficacy and safety, dosing, and the evidence behind any first-in-class or best-in-class claim.
- Rights and economics: Establish the territory covered, development responsibilities, and any disclosed upfront payment, milestones, or royalties. Do not assume undisclosed terms.
- Cross-border execution: Consider data access and transfer, regulatory pathways, multinational trial design, intellectual-property and know-how transfer, geopolitical exposure, and post-deal integration.
BCG’s 2026 analysis emphasizes that companies entering emerging innovation hubs need biological expertise alongside experience designing multinational trials. It also points to the need to adapt integration for culturally diverse teams, use patient data from outside the United States, and navigate a more difficult geopolitical environment for multinational collaboration. These are operational considerations, not evidence that a particular transaction has encountered a problem.
Why China-originated trial results may not settle the question
Data from a trial conducted in China may be important, but a buyer still has to judge whether the findings apply to the populations, clinical settings, and regulatory requirements relevant to future development and sales. Trial design, patient populations, and comparative evidence matter alongside headline efficacy results.
BeInCrypto’s October 7, 2026, account pointed to Summit Therapeutics’ HARMONi-3 lung-cancer trial against Merck’s Keytruda as a test of whether China-originated clinical evidence translates in Western patients. The outlet reported that further squamous-tumor data were expected in the second half of 2026 and that an April interim analysis had not delivered an early win. Those are secondary-report claims, not a verified statement of the trial’s current status; they should not be treated as a definitive clinical conclusion.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What this trend means for readers following the industry
The available evidence supports a broad conclusion: large biopharma companies have reasons to seek external innovation, and China has become a substantial source of biotech candidates and licensing activity. It does not support claims that a named company is negotiating for a named China-originated asset unless a separate, attributable report establishes that specific link. For investors, the market-level trend is context—not a substitute for evaluating a company’s disclosed deal terms, clinical evidence, development obligations, and risks.
Recommended Free Tools
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
